专蛋白:临床使用的全面审查和实践指南
Farshad Abedi1, Batool Zarei2, Sepideh Elyasi3
1Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, P.O. Box, Mashhad, 91775-1365, Iran.
European journal of clinical pharmacology
|April 12, 2024
概括
专主要用于肝病并发症和在休克状态下液体复苏. 证据支持其用于肝硬化,但其他迹象的建议较弱,强调指导方针的实施.
科学领域:
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
- 关键护理医学 关键护理医学
背景情况:
- 专在低专血症和营养支持中的作用在很大程度上被毁了.
- 目前的辩论重点是白蛋白在休克状态,特别是败血症休克中的有用性.
- 肝脏疾病的管理仍然是阿尔伯明的管理的一个关键的基于证据的指示.
研究的目的:
- 为提供最新的,基于证据的阿尔伯明的使用说明.
- 概述专使用的确切和潜在的临床适用性.
- 为了确定合适的剂量和阿尔伯明治疗的持续时间.
主要方法:
- 在PubMed,谷歌学者,Scopus和科学网的综合文献搜索到2023年11月.
- 利用GRADE系统来评估证据质量和建议的强度.
- 包括165项相关研究进行审查.
主要成果:
- 强有力的证据支持在肝病并发症 (肝综合征,自发性细菌周周炎,大体积体) 中使用白蛋白.
- 专蛋白显示低到中等的证据,以及在各种冲击状态,严重烧伤和水中对液体复苏的弱建议.
- 具体用途,如适度体积抛膜和肝硬化时的低血,证据有限.
结论:
- 专最适用于治疗肝硬化的并发症.
- 合理的用途包括液体复苏和治疗对其他疗法无反应的低albuminemic 患者的耐火性水.
- 实施基于证据的指导方针可以制不适当的白蛋白使用.
相关概念视频
Drug Distribution: Plasma Protein Binding
5.5K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.5K
Hepatic Drug Clearance: Effect of Protein Binding
194
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
194
Factors Affecting Protein-Drug Binding: Patient-Related Factors
57
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
57
Factors Affecting Protein-Drug Binding: Protein-Related Factors
156
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
156
Drug Binding to Blood Components
147
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
147
Protein-Drug Binding: Mechanism and Kinetics
447
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
447


